Drug Profile
Research programme: CRAC channel antagonists - CalciMedica
Alternative Names: CRAC channel inhibitors - CalciMedicaLatest Information Update: 06 Nov 2023
Price :
$50
*
At a glance
- Originator CalciMedica
- Class Small molecules
- Mechanism of Action Immunosuppressants; ORAI1 protein inhibitors; STIM1 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Autoimmune disorders; Inflammation; Stroke
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for preclinical development in Stroke in USA (Parenteral)
- 16 Nov 2020 Pharmacodynamics data from a preclinical trial in Stroke released by CalciMedica
- 17 Jul 2020 CalciMedica and Epipharma enters research collaboration for development of CRAC channel inhibitors